[Mycobacterium ulcerans infection in man (Baruli-ulcer)].
D000814:Aniline Compounds / Q000627:therapeutic use; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000175:diagnosis; D008297:Male; D009164:Mycobacterium Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control; D010619:Phenazines / Q000627:therapeutic use; D011379:Prognosis; D051381:Rats; D012874:Skin Diseases, Infectious / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control; D014329:Tropical Climate; D014330:Tropical Medicine
D000814:Aniline Compounds; D000890:Anti-Infective Agents; D010619:Phenazines
Die Infektion des Menschen mit Mycobacterium ulcerans (Buruli-Ulkus.